Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: A single center experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Yoon, D.H. | - |
dc.contributor.author | Park, I. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Park, J.S. | - |
dc.contributor.author | Lee, S.-W. | - |
dc.contributor.author | Huh, J. | - |
dc.contributor.author | Park, C.-S. | - |
dc.contributor.author | Suh, C. | - |
dc.date.available | 2020-02-28T18:44:51Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/13003 | - |
dc.description.abstract | Background: Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controversial. Methods: We retrospectively reviewed the medical records of 14 patients with primary testicular DLBCL diagnosed between November 2000 and June 2012, and analyzed the CNS relapse rate in patients treated without intrathecal prophylaxis. Survival curves were estimated using the Kaplan-Meier method. Results: The median age at diagnosis was 57 years (range, 41-79 years). Unilateral testicular involvement was observed in 13 patients. Nine patients had stage I, 1 had stage II, and 4 had stage IV disease. The international prognostic index was low or low-intermediate risk in 12 patients and high-intermediate risk in 2 patients. Thirteen patients underwent orchiectomy. All the patients received systemic chemotherapy without intrathecal prophylaxis, and prophylactic radiotherapy was administered to the contralateral testis in 12 patients. The median follow-up period of surviving patients was 39 months (range, 10-139 months). Median overall survival was not reached and the median progression-free survival was 3.8 years. Four patients experienced relapse, but CNS relapse was observed in only one patient (7.1%) with stage IV disease, 27 months after a complete response. Conclusion: Even without intrathecal prophylaxis, the rate of relapse in the CNS was lower in the Korean patients with primary testicular DLBCL compared to prior reports. © 2014 Korean Society of Hematology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.relation.isPartOf | Blood Research | - |
dc.subject | cisplatin | - |
dc.subject | cyclophosphamide | - |
dc.subject | cytarabine | - |
dc.subject | dexamethasone | - |
dc.subject | doxorubicin | - |
dc.subject | etoposide | - |
dc.subject | methotrexate | - |
dc.subject | methylprednisolone | - |
dc.subject | prednisolone | - |
dc.subject | rituximab | - |
dc.subject | vincristine | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | Article | - |
dc.subject | cancer chemotherapy | - |
dc.subject | cancer radiotherapy | - |
dc.subject | cancer recurrence | - |
dc.subject | cancer staging | - |
dc.subject | cancer survival | - |
dc.subject | clinical article | - |
dc.subject | follow up | - |
dc.subject | human | - |
dc.subject | International Prognostic Index | - |
dc.subject | large cell lymphoma | - |
dc.subject | lymph node metastasis | - |
dc.subject | male | - |
dc.subject | meningeal metastasis | - |
dc.subject | orchiectomy | - |
dc.subject | overall survival | - |
dc.subject | primary tumor | - |
dc.subject | progression free survival | - |
dc.subject | testis cancer | - |
dc.subject | treatment outcome | - |
dc.subject | treatment response | - |
dc.title | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: A single center experience | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.5045/br.2014.49.3.170 | - |
dc.identifier.bibliographicCitation | Blood Research, v.49, no.3, pp.170 - 176 | - |
dc.identifier.kciid | ART001911594 | - |
dc.identifier.scopusid | 2-s2.0-84911431316 | - |
dc.citation.endPage | 176 | - |
dc.citation.startPage | 170 | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 49 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Park, I. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | Intrathecal prophylaxis | - |
dc.subject.keywordAuthor | Primary testicular lymphoma | - |
dc.subject.keywordPlus | cisplatin | - |
dc.subject.keywordPlus | cyclophosphamide | - |
dc.subject.keywordPlus | cytarabine | - |
dc.subject.keywordPlus | dexamethasone | - |
dc.subject.keywordPlus | doxorubicin | - |
dc.subject.keywordPlus | etoposide | - |
dc.subject.keywordPlus | methotrexate | - |
dc.subject.keywordPlus | methylprednisolone | - |
dc.subject.keywordPlus | prednisolone | - |
dc.subject.keywordPlus | rituximab | - |
dc.subject.keywordPlus | vincristine | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer radiotherapy | - |
dc.subject.keywordPlus | cancer recurrence | - |
dc.subject.keywordPlus | cancer staging | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | International Prognostic Index | - |
dc.subject.keywordPlus | large cell lymphoma | - |
dc.subject.keywordPlus | lymph node metastasis | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | meningeal metastasis | - |
dc.subject.keywordPlus | orchiectomy | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | primary tumor | - |
dc.subject.keywordPlus | progression free survival | - |
dc.subject.keywordPlus | testis cancer | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | treatment response | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.